PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

46,012 stories, page 693 of 767

Advanced search
🇺🇰Researchuclh.nhs.ukTier 2 · Direct publisher

First patient recruited to Phase I Early Alzheimer’s Disease study

University College London Hospitals (UCLH)Original source
🌍Industryir.talphera.comTier 1 · Company source

Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TalpheraOriginal source
🌍Mediainsitro.comTier 2 · Direct publisher

Rewriting the Playbook for ALS Drug Development

InsitroOriginal source
🌍Mediainsitro.comTier 2 · Direct publisher

insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets

InsitroOriginal source
🌍Industryaptose.comTier 1 · Company source

Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement

Aptose BiosciencesOriginal source
🇩🇪Researchcharite.deTier 2 · Direct publisher

Launch of the Einstein Center for Early Disease Interception

Charité - Universitätsmedizin Berlin (EN)Original source
🌍Industryir.biolinerx.comTier 1 · Company source

BioLineRx Reports 2025 Financial Results and Provides Corporate Update

BioLineRxOriginal source
🇯🇵Deviceshoya.comTier 1 · Company source

HOYA Introduces Its First Off-site Corporate PPA at Akishima Plant

HOYA CorporationOriginal source
🇯🇵Deviceshoya.comTier 1 · Company source

オフサイトコーポレートPPAによる再生可能エネルギーを昭島工場に導入

HOYA MedicalOriginal source
🌍Mediaechonous.comTier 2 · Direct publisher

Enhancing Patient Safety in Labor and Delivery with Point-of-Care Ultrasound

EchoNousOriginal source
🇺🇸Industryneogenomics.comTier 1 · Company source

Oncology data solutions

NeoGenomicsOriginal source
🌍Deviceschembio.comTier 3 · Secondary coverage

QUALIGEN DIAGNOSTICS ANNOUNCE AGREEMENT WITH AFAXYS GPO TO EXPAND ACCESS TO FASTPACK® IP QUANTITATIVE hCG TESTING IN WOMEN’S HEALTH

Chembio Diagnostics, Inc.Original source
🌍Mediaproscia.comTier 2 · Direct publisher

Why Precision Medicine Needs an Enterprise Digital Pathology Backbone, Not Just a Vendor

ProsciaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

Clinical Genomic Services & Diagnostic Support | Congenica

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

SeqOne Blog | Insights on AI-Powered Genomic Analysis & Clinical Innovation

CongenicaOriginal source
🇺🇸Researchmdanderson.orgTier 2 · Direct publisher

How to find the right therapist for you

MD Anderson Cancer CenterOriginal source
🌍Industrypiindustries.comTier 1 · Company source

Herbicides: Complete Guide to Modern Weed Control in Agriculture

PI Industries (Pharma)Original source
🇫🇷Industrycellectis.comTier 1 · Company source

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

CellectisOriginal source
🇮🇱Industryir.tevapharm.comTier 1 · Company source

Teva Releases Q1 2026 Aide Memoire

Teva Pharmaceuticals RSSOriginal source
🌍Industryrelmada.comTier 1 · Company source

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Relmada TherapeuticsOriginal source
🌍Researchopenclinica.comTier 2 · Direct publisher

The CRO That Walks In With a Platform Wins the Room

OpenClinicaOriginal source
🇫🇷Industrypierre-fabre.comTier 1 · Company source

Laboratoires Pierre Fabre confirms the strength of its business model and is stepping up its investments in innovation and production

Pierre FabreOriginal source
🇺🇸Industrybambusatx.comTier 1 · Company source

Bambusa Therapeutics Appoints Todd James Chief Financial Officer

Bambusa TherapeuticsOriginal source
🇺🇸CDMOveranex.comTier 2 · Direct publisher

Veranex Appoints Megan Osorio as Chief Executive Officer

VeranexOriginal source
🌍Industryaptose.comTier 1 · Company source

Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical

Aptose BiosciencesOriginal source
🇩🇰Regulatorylaegemiddelstyrelsen.dkTier 1 · Regulatory source

PRAC assesses that NAION could be a very rare side effect of Ozempic, Rybelsus and Wegovy

Danish Medicines AgencyOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

Notice of Board of Director and Corporate Auditor Nominations

Santen PharmaceuticalOriginal source
🇨🇦Mediainnovativemedicines.caTier 2 · Direct publisher

IMC Statement on New Federal Government Task Force

Innovative Medicines CanadaOriginal source
🌍Industryir.talphera.comTier 1 · Company source

Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026

TalpheraOriginal source
🇺🇸Devicesfoundationmedicine.comTier 1 · Company source

A High-Quality Testing Portfolio Grounded in Science – A Research Recap

Foundation MedicineOriginal source
🇯🇵CROen.cmicgroup.comTier 2 · Direct publisher

Celltrion Healthcare Japan and CMIC Group Enter Strategic Partnership to Expand Biosimilars in Japan

CMIC Group JapanOriginal source
🇺🇸CROcaidya.comTier 2 · Direct publisher

Bridging Regulatory Systems: From China’s IND to Europe’s CTA

Caidya (Clinipace)Original source
🇨🇦Researchgenomecanada.caTier 2 · Direct publisher

Canada invests in genomics R&D to accelerate industry growth and technology adoption

Genome CanadaOriginal source
🌍Industryinvestors.xoma.comTier 1 · Company source

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

Xoma CorporationOriginal source
🌍Industryuk-cpi.comTier 1 · Company source

UK HealthTech Industrial Council marks first year accelerating innovation, investment and collaboration across the MedTech sector

CPI (Healthcare Innovation)Original source
🌍Researchunityhealth.toTier 2 · Direct publisher

How St. Michael’s Hospital became “home” to a patient

St. Michael's Hospital (Toronto)Original source
🇪🇺Associationeucope.orgTier 2 · Direct publisher

EUCOPE reacts to the vote on the provisional agreement on the EU General Pharmaceutical Legislation (GPL)

EUCOPEOriginal source
🌍CROcrucialdatasolutions.comTier 2 · Direct publisher

What Are the Requirements for Virtual (Electronic) Informed Consent?

TrialKitOriginal source
🌍Regulatorytransceleratebiopharmainc.comTier 1 · Regulatory source

Making AI work where it matters, with Rob DiCicco

TransCelerate BioPharmaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

Genomic analysis of adult thrombotic microangiopathies in less than 3 days: from rapid to fast genomics to treatment

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

SeqOne GenomeAlert! A variant reevaluation automation agent to improve patient care

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

Genome Alert!: A standardized procedure for genomic variant reinterpretation and automated gene–phenotype reassessment in clinical routine

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

Fine mapping of RNA isoform diversity using an innovative targeted long-read RNA sequencing protocol with novel dedicated bioinformatics pipeline

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

Exome sequencing as a first-tier test for copy number variant detection: retrospective evaluation and prospective screening in 2418 cases

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

Delivering Personalized Oncology for Patients: Integrating Molecular Signatures in Clinical Practice

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

DE-kupl: exhaustive capture of biological variation in RNA-seq data through k-mer decomposition

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

Clinical and Molecular Spectrum of Nonsyndromic Early-Onset Osteoarthritis

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

Transforming Patient Care: SeqOne Empowers CHU de Reims with Advanced Genomic Analysis

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

Beyond the Exome: How One Lab is Democratizing Whole Genome Sequencing in Eastern Europe

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

Precision Medicine at Scale: AP-HM’s Automated Exome Analysis Success Story

CongenicaOriginal source
🇺🇰Industrycongenica.comTier 1 · Company source

AI in Clinical Genomics: The Science and Real-World Impact of AI on Variant Interpretation

CongenicaOriginal source
🇫🇷CDMOaxplora.comTier 3 · Secondary coverage

Biopharma’s Growing Emphasis on Highly Potent Drugs Drives Axplora Manufacturing Expansion

NovasepOriginal source
🌍Industryuk-cpi.comTier 1 · Company source

CPI and Medicines Discovery Catapult launch project to unlock faster, lower-risk development of next-generation RNA medicines

CPI (Healthcare Innovation)Original source
🌍Mediascience37.comTier 2 · Direct publisher

Science 37 Launches Dedicated Pediatrics Department to Expand Access to Specialized Clinical Research for Children and Families

Science 37Original source
🌍Industryalloytx.comTier 1 · Company source

Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform

Alloy TherapeuticsOriginal source
🇺🇸Industryvikingtherapeutics.comTier 1 · Company source

Prevalence of Cardiovascular-Kidney-Metabolic Conditions Across Body Mass Index Categories: The Distinct Burden of Severe (Class III) Obesity - Viking Therapeutics

Viking Therapeutics (IR)Original source
🌍CROcrucialdatasolutions.comTier 2 · Direct publisher

A Guide to Medical Coding in Clinical Trials

TrialKitOriginal source
🇺🇸Devicesaccuray.comTier 1 · Company source

AI in Radiation Oncology: What It Takes to Deploy Responsibly

AccurayOriginal source
🌍Regulatoryinfarma.plTier 1 · Regulatory source

Przekształcenie potencjału naukowego UE w sukces komercyjny mogłoby dodać 120 mld euro do gospodarki UE w ciągu 10 lat

INFARMA PolandOriginal source